Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01284192 · ClinicalTrials.gov registry record · Phase 1

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

A Phase 1 study of Solid Tumor and B-cell Lymphoma, sponsored by Astellas Pharma.

Completed
Registry status
Phase 1
Development phase
46
Enrollment target
6
Study locations

NCT01284192 is a Phase 1 study of Solid Tumor and B-cell Lymphoma that has completed, run by Astellas Pharma. The registered enrollment target is 46 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (79% lower). The trial reports 6 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01284192, a Phase 1 study of Solid Tumor and B-cell Lymphoma, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 1
Development phase
46 participants
Enrollment target
6
Study locations

Study Summary

This study is to evaluate the safety and anti-tumor activity of ASP3026 in patients with advanced malignancies (solid tumors and B-cell lymphoma).

Conditions Studied

Solid Tumor B-cell Lymphoma Advanced Malignancies Positive for Anaplastic Lymphoma Kinase Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS

Interventions

  • DRUG ASP3026

Study Locations (6)

California

  • Site US160 - Orange
  • Site US184 - Sacramento

Texas

  • Site US2492 - Houston
  • Site US1905 - San Antonio

Illinois

  • Site US11 - Chicago

Michigan

  • Site US2688 - Detroit

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2010-12
Est. Completion 2016-03
Phase Phase 1

Sponsor

Astellas Pharma

165 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01284192

The ClinicalTrials.gov registry entry for NCT01284192 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (79% lower). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which ASP3026 is the first listed.

NCT01284192 reports 6 study locations spanning 4 distinct geographic areas - top geographies include California, Texas, Illinois.

Frequently Asked Questions

What is clinical trial NCT01284192 about?

NCT01284192 is a clinical study titled "Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)". This study is to evaluate the safety and anti-tumor activity of ASP3026 in patients with advanced malignancies (solid tumors and B-cell lymphoma).

What is the current status of trial NCT01284192?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2010-12. Estimated completion is 2016-03.

What conditions does trial NCT01284192 study?

This clinical trial studies the following conditions: Solid Tumor, B-cell Lymphoma, Advanced Malignancies, Positive for Anaplastic Lymphoma Kinase, Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS.

What interventions are being tested in trial NCT01284192?

The interventions under investigation include: ASP3026 (DRUG).

Who is sponsoring clinical trial NCT01284192?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01284192 being conducted?

This trial has 6 study locations across California, Illinois, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor

All registered trials for this condition

B-cell Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.